Use of Antithrombin and Thrombomodulin in the Management of Disseminated Intravascular Coagulation in Patients with Acute Cholangitis
2
조회
0
다운로드
0
인용
0
참고문헌
초록
Background/Aims: To evaluate the usefulness and safety of treating disseminated intravascular coagulation (DIC) complicating cholangitis primarily with antithrombin (AT) and thrombomodulin (rTM). Methods: A DIC treatment algorithm was determined on the basis of plasma AT III levels at the time of DIC diagnosis and DIC score changes on treatment day 3. Laboratory data and DIC scores were assessed prospectively at 2-day intervals. Results: DIC reversal rates >75%were attained on day 7. In the DIC reversal group, statistically significant differences from baseline were observed in interleukin-6 and C-reactive protein levels within 5 days. Patients with no DIC score improvements after treatment with AT alone experienced slow improvement on a subsequent combination therapy with rTM. Although a subgroup with biliary drainage showed greater improvement in DIC scores than did the nondrainage subgroup, the mean DIC score showed improvement even in the nondrainage subgroup alone. Gastric cancer bleeding that was treated conservatively occurred in one patient. As for day 28 outcomes, three patients died from concurrent malignancies. Conclusions: Although this algorithm was found to be useful and safe for DIC patients with cholangitis, it may be better to administer rTM and AT simultaneously from day 1 if the plasma AT III level is less than 70%.
Abstract
Background/Aims: To evaluate the usefulness and safety of treating disseminated intravascular coagulation (DIC) complicating cholangitis primarily with antithrombin (AT) and thrombomodulin (rTM). Methods: A DIC treatment algorithm was determined on the basis of plasma AT III levels at the time of DIC diagnosis and DIC score changes on treatment day 3. Laboratory data and DIC scores were assessed prospectively at 2-day intervals. Results: DIC reversal rates >75%were attained on day 7. In the DIC reversal group, statistically significant differences from baseline were observed in interleukin-6 and C-reactive protein levels within 5 days. Patients with no DIC score improvements after treatment with AT alone experienced slow improvement on a subsequent combination therapy with rTM. Although a subgroup with biliary drainage showed greater improvement in DIC scores than did the nondrainage subgroup, the mean DIC score showed improvement even in the nondrainage subgroup alone. Gastric cancer bleeding that was treated conservatively occurred in one patient. As for day 28 outcomes, three patients died from concurrent malignancies. Conclusions: Although this algorithm was found to be useful and safe for DIC patients with cholangitis, it may be better to administer rTM and AT simultaneously from day 1 if the plasma AT III level is less than 70%.
참고문헌 (15)
- Wada H, "Expert consensus for the treatment of disseminated intravascular coagulation in Japan", Thromb Res, 125, pp.6~11 (2010)
- Gando S, "A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria", Crit Care Med, 34, pp.625~631 (2006)
- Wiedermann CJ, "Clinical review: molecular mechanisms underlying the role of antithrombin in sepsis", Crit Care, 10, pp.209~ (2006)
- Opal SM, "Antithrombin, heparin, and heparan sulfate", Crit Care Med, 30(5 Suppl), pp.S325~S331 (2002)
- Mavrommatis AC, "Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock", Intensive Care Med, 27, pp.1853~1859 (2001)
- Warren BL, "Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial", JAMA, 286, pp.1869~1878 (2001)
- Kienast J, "Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation", J Thromb Haemost, 4, pp.90~97 (2006)
- Saito H, "Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial", J Thromb Haemost, 5, pp.31~41 (2007)
- Esmon NL, "Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C", J Biol Chem, 257, pp.859~864 (1982)
- Bernard GR, "Efficacy and safety of recombinant human activated protein C for severe sepsis", N Engl J Med, 344, pp.699~709 (2001)
- Abeyama K, "The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism", J Clin Invest, 115, pp.1267~1274 (2005)
- Ito T, "Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes", Arterioscler Thromb Vasc Biol, 28, pp.1825~1830 (2008)
- Aikawa N, "Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial", Shock, 35, pp.349~354 (2011)
- Eguchi Y, "Efficacy of recombinant thrombomodulin in antithrombin substitution-resistant septic disseminated intravascular coagulation: results of a pilot study", J Jpn Soc Surg Infect, 7, pp.143~148 (2010)
- Wang H, "HMG-1 as a late mediator of endotoxin lethality in mice", Science, 285, pp.248~251 (1999)